Linkedin Corp. (LNKD: Quote) gained 8 percent to $117.99. The company's first quarter profit and revenues doubled from the year-ago quarter and were above Wall Street view. The company guided second quarter revenue above consensus, while raising its fiscal year 2012 revenue guidance. The company also announced that it agreed to acquire SlideShare, a professional content sharing community, in a transaction valued at approximately $118.75 million.
Einstein Noah Restaurant Group, Inc. (BAGL: Quote) rose 29 percent to $18.10 based on the news that it plans review of strategic alternatives, including a possible business combination or sale of the company. The company's first quarter earnings and revenues improved from the last year quarter.
Dolby Laboratories, Inc. (DLB: Quote) increased 18 percent to $44.49 amidst the news that Microsoft (MSFT) has selected Dolby Digital Plus to create audio experiences for Windows 8 on Tablets And PCs. The company's first quarter profit and revenue increased from the prior year period and also were above Wall Street view.
American International Group, Inc. (AIG: Quote) fell 1 percent to $33.80. The company's first quarter net income attributable to the company and its after-tax operating income surged from the previous year period.
First Solar, Inc. (FSLR: Quote) declined 1 percent $17.90. The company slipped to a loss in its first quarter. Net sales declined from the year-ago quarter and was below consensus. Meanwhile, the company raised its fiscal 2012 earnings per share guidance. The company also announced that it has appointed James Hughes as its Chief Executive Officer.
Body Central Corp. (BODY: Quote) plunged 30 percent to $20.25 as the company expects its second quarter and full fiscal year results below Wall Street view. The company's first quarter earnings per share were in-line with analysts' estimate. Net revenues for the quarter increased 11.8 percent.
Alexza Pharmaceuticals, Inc. (ALXA: Quote) declined 42 percent to $0.35. The company has received a Complete Response Letter from the FDA regarding its New Drug Application for ADASUVE inhalation powder, 5 mg and 10 mg, indicating that the application is not ready for approval in its present form.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org